07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Sunday that long-term results from a phase 3 trial of Keytruda as treatment for advanced melanoma showed "sustained improved survival outcomes."

The 10-year overall survival rate for Keytruda was 34%, higher than 23.6% for alternative drug ipilimumab, Merck ( MRK ) said. The median OS for Keytruda-treated patients was 32.7 months, compared with 15.9 months for ipilimumab.

Keytruda also reduced the risk of death by 29%, according to Merck ( MRK ).

Price: 115.56, Change: +0.47, Percent Change: +0.41